Pfizer said the decision upholding the exclusivity of the patent covering atorvastatin until November 2011 was an important victory for scientists. For pharmacists, while generic atorvastatin may be a boon for pharmacy margins, the transfer of $7. 4 billion from the branded drug market to the generics arena would spell a significant downturn in same-store pharmacy sales. NEW YORK — Pfizer atorvastatin lipitor patent inc. Such factors are detailed from time to time in Nymox’s filings with the United States Securities and Exchange Atorvastatin lipitor patent commission and other regulatory authorities. Pfizer faces a potentially more serious threat to Lipitor. Cinfa, Kern, Alter and Belmac can seek to appeal the decision to the Supreme Court of Spain. MAYWOOD, N. The Company markets NicAlert(TM) and TobacAlert(TM) tests for measuring tobacco product exposure. The decision prevents Ranbaxy from launching its drug before Lipitor’s atorvastatin lipitor patent basic patent (EP 247,633) expires in November 2011. Ranbaxy vice president Charles Caprariello said the company would appeal the ruling that upheld the main patent. The decision — which resulted from a patent atorvastatin lipitor patent challenge by generic manufacturers Ranbaxy Laboratories Limited and Basics GmbH — has no immediate commercial impact because neither company has regulatory approval to sell a generic atorvastatin product in Germany, and because Pfizer’s basic patent covering atorvastatin remains in force, and expires after the enantiomer patent. Contributing: Jane Wardell NEW YORK — Pfizer Inc said today that it will seek to appeal a ruling of the Court of Appeal of The Hague in the Netherlands that Pfizer’s atorvastatin enantiomer patent is invalid. Won a significant victory on Wednesday when a British judge upheld a key patent covering its blockbuster cholesterol drug Lipitor in the United Kingdom, but the medication still faces a similar yet atorvastatin lipitor patent more important case in the United States. And Laboratorios Belmac S. , and is one of four atorvastatin lipitor patent separate challenges to the enantiomer patent by generic companies in Spain. Pharmacy benefit manager Express Scripts Inc. With its 2003 launch of Crestor and clinical claims that Crestor works as well as Lipitor–if not better–in lowering low-density lipoproteins, there is a strong possibility Crestor could become the atorvastatin lipitor patent most-prescribed prescription statin on the market. Statins are widely prescribed cholesterol-lowering drugs with a good Atorvastatin lipitor patent safety profile and with estimated global sales of up to $26 billion last year. Pfizer said it will continue to vigorously defend its patents against infringement. Supplier News — Pfizer may be able to maintain the patents protecting the best-selling pharmaceutical in the world following a federal judge ruling last month against Ranbaxy Laboratories. Other scientific and clinical studies have showed the potential benefits of statin drugs in the prevention or treatment of Alzheimer’s disease.